Patterns and significance of exhaled-breath biomarkers in lung transplant recipients with acute allograft rejection

Studer, Sean M.; Orens, Jonathan B.; Rosas, IO; Krishnan, Jerry A.; Cope, Keary A.; Su, Yang; Conte, John V.; Becker, Penny; Risby, Terence H.

doi:10.1016/s1053-2498(01)00343-6

Cited by 111 publications

(72 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study found that eNO increased during acute vascular rejection [11], while the other found an elevation during lymphocytic bronchiolitis but not during acute vascular rejection [12]. A recent study reported elevated levels of exhaled carbonyl sulphide in association with acute rejection, but data showed a large overlap with values obtained in stable patients [13].…”

Section: The Diagnosis Of Acute Rejectionmentioning

confidence: 94%

Immunosuppressive therapy after human lung transplantation

Knoop¹,

Haverich²,

Fischer³

2004

European Respiratory Journal

View full text Add to dashboard Cite

numbers of lung transplantation (LTx) were performed with or without induction therapy with antilymphocyte antibodies, monoclonal anti-CD3 antibody or anti-interleukin-2-receptor monoclonal antibodies. It remains to be established if induction therapy after LTx is beneficial or deleterious for long-term graft and patient survival.The vast majority of lung transplant recipients receive a triple-drug maintenance regimen including a calcineurin inhibitor, a cell-cycle inhibitor and steroids. Equal proportions receive cyclosporin A (CsA) and tacrolimus (Tac). There is also a trend to prescribe mycophenolate mofetil (MMF) instead of azathioprine (Aza). Steroid withdrawal is uncommon even 5 yrs after transplantation.The superiority of Tac over CsA as a maintenance agent has not been established to date, and the administration of MMF instead of Aza in combination with CsA and steroids did not improve graft or patient survival in a recent international, prospective, randomised, controlled trial.Shift from cyclosporin A to tacrolimus has emerged as the first treatment step of refractory acute rejection followed by high-dose steroids or antilymphocyte agents, total lymphoid irradiation or photopheresis. The treatment of chronic rejection remains deceptive and includes varied strategies such as modification of the maintenance regimen, addition of inhaled immunosuppressants and/or total lymphoid irradiation and photopheresis. Eur Respir J 2004; 23: 159-171.

show abstract

Section: The Diagnosis Of Acute Rejectionmentioning

confidence: 94%

Immunosuppressive therapy after human lung transplantation

Knoop¹,

Haverich²,

Fischer³

2004

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…origins and it is the most prevalent sulfur gas in the atmosphere (152). COS is the only volatile sulfur that is increased in exhaled air of patients with cystic fibrosis (69) or of lung transplant patients during the acute rejection phase (150). COS is also exhaled by patients with chronic liver disease (135).…”

Section: Other Potential Biosynthetic Pathwaysmentioning

confidence: 99%

The therapeutic potential of hydrogen sulfide: separating hype from hope

Olson

2011

American Journal of Physiology-Regulatory, Integrative and Comp

162

154

View full text Add to dashboard Cite

Hydrogen sulfide (H2S) has become the hot new signaling molecule that seemingly affects all organ systems and biological processes in which it has been investigated. It has also been shown to have both proinflammatory and anti-inflammatory actions and proapoptotic and anti-apoptotic effects and has even been reported to induce a hypometabolic state (suspended animation) in a few vertebrates. The exuberance over potential clinical applications of natural and synthetic H2S-“donating” compounds is understandable and a number of these function-targeted drugs have been developed and show clinical promise. However, the concentration of H2S in tissues and blood, as well as the intrinsic factors that affect these levels, has not been resolved, and it is imperative to address these points to distinguish between the physiological, pharmacological, and toxicological effects of this molecule. This review will provide an overview of H2S metabolism, a summary of many of its reported “physiological” actions, and it will discuss the recent development of a number of H2S-donating drugs that show clinical potential. It will also examine some of the misconceptions of H2S chemistry that have appeared in the literature and attempt to realign the definition of “physiological” H2S concentrations upon which much of this exuberance has been established.

show abstract

“…To date, eicosanoids, products of lipid peroxidation, vasoactive amines, nitric oxide (NO)-related products, ammonia, hydrogen ions and cytokines have been measured, and there is hope that this method may contribute to the early detection of BOS in the future. Only exhaled carbonyl sulphide as a marker of acute rejection [137] and leukotriene B 4 as a marker of infection [138] have been described in the lung transplant population.…”

Section: Exhaled Breath Condensatementioning

confidence: 99%

Post-transplant bronchiolitis obliterans

Boehler

Estenne²

2003

European Respiratory Journal

177

105

View full text Add to dashboard Cite

Over the last decade, improvements in surgical techniques, lung preservation, immunosuppression, and management of ischaemia/reperfusion injury and infections have made intermediate-term survival after lung transplantation an achievable goal. However, chronic allograft dysfunction in the form of bronchiolitis obliterans remains a major hurdle that threatens both the quality of life and long-term survival of the recipients. It affects up to 50-60% of patients who survive 5 yrs after surgery, and it accounts for w30% of all deaths occurring after the third postoperative year.This article discusses the alloimmune-dependent and -independent risk factors for bronchiolitis obliterans, the current understanding of the pathogenesis of bronchiolitis obliterans based on results of animal and human studies, the clinical staging of the complication, strategies that may contribute to the prevention and/or early detection of bronchiolitis obliterans, and suggestions for future research.

show abstract

Patterns and significance of exhaled-breath biomarkers in lung transplant recipients with acute allograft rejection

Cited by 111 publications

References 21 publications

Immunosuppressive therapy after human lung transplantation

Immunosuppressive therapy after human lung transplantation

The therapeutic potential of hydrogen sulfide: separating hype from hope

Post-transplant bronchiolitis obliterans

Contact Info

Product

Resources

About